Tetragon Partners GP Ltd holds a concentrated book of 34 stocks worth $508.9M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Warner Bros Discovery Inc and trimmed Kolibri Global Energy Inc. Their largest long position is Uipath Inc - Class A at 55% of the equity book. They also disclosed $6.2M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1515070/holdings"
Use Arkolith to show Tetragon Partners GP Ltd's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Uipath Inc CL A | $279.8M | 25.21M | 55.0% | ▲+44% Added · +7.8M sh | |
| 2 | Kolibri Global Energy Inc COM NEW | $37.5M | 6.83M | 7.4% | ▼−1.4% Reduced · −100K sh | |
| 3 | Warner Bros Discovery Inc COM SER A | $25.4M | 923.7K | 5.0% | ▲New New position | |
| 4 | Workiva Inc COM CL A | $14.9M | 250.0K | 2.9% | ▲+67% Added · +100K sh | |
| 5 | Lyft Inc CL A COM | $13.3M | 1.00M | 2.6% | —Held | |
| 6 | Sprinklr Inc CL A | $13.2M | 2.20M | 2.6% | —Held | |
| 7 | Autolus Therapeutics Ltd SPON ADS | $13.1M | 9.50M | 2.6% | —Held | |
| 8 | Celldex Therapeutics Inc New COM NEW | $9.9M | 312.3K | 1.9% | ▲+28% Added · +69K sh | |
| 9 | Arrowhead Pharmaceuticals In COM | $8.0M | 127.2K | 1.6% | ▲+31% Added · +30K sh | |
| 10 | Nektar Therapeutics COM NEW | $7.4M | 103.0K | 1.5% | ▲+49% Added · +34K sh | |
| 11 | Annexon Inc COM | $7.2M | 1.29M | 1.4% | ▼−36% Reduced · −740K sh | |
| 12 | Pharvaris N V COM | $6.3M | 221.6K | 1.2% | ▲+14% Added · +27K sh | |
| 13 | Alkermes PLC SHS | $5.7M | 159.8K | 1.1% | ▲+13% Added · +19K sh | |
| 14 | Agios Pharmaceuticals Inc COM | $5.6M | 164.8K | 1.1% | ▲+1.7% Added · +3K sh | |
| 15 | Immunovant Inc COM | $5.4M | 218.5K | 1.1% | ▲+31% Added · +52K sh | |
| 16 | Praxis Precision Medicines I COM NEW | $5.1M | 16.0K | 1.0% | ▼−30% Reduced · −7K sh | |
| 17 | Krystal Biotech Inc COM | $5.1M | 19.7K | 1.0% | ▲+66% Added · +8K sh | |
| 18 | Dyne Therapeutics Inc COM | $4.7M | 258.1K | 0.9% | ▲+4.1% Added · +10K sh | |
| 19 | Amylyx Pharmaceuticals Inc COM | $4.4M | 317.9K | 0.9% | ▲+17% Added · +45K sh | |
| 20 | MBX Biosciences Inc COM | $4.3M | 145.5K | 0.9% | ▲+1.5% Added · +2K sh | |
| 21 | Definium Therapeutics Inc COM SHS | $3.8M | 200.0K | 0.7% | ▲New New position | |
| 22 | Soleno Therapeutics Inc COM | $3.4M | 102.1K | 0.7% | ▲New New position | |
| 23 | Axsome Therapeutics Inc. COM | $3.4M | 20.1K | 0.7% | ▼−26% Reduced · −7K sh | |
| 24 | Harmony Biosciences Hldgs In COM | $3.3M | 119.3K | 0.7% | ▲+44% Added · +37K sh | |
| 25 | Silence Therapeutics PLC ADS | $3.3M | 630.2K | 0.7% | ▲+72% Added · +265K sh | |
| 26 | Acadia Pharmaceuticals Inc COM | $3.2M | 144.6K | 0.6% | ▲New New position | |
| 27 | Ionis Pharmaceuticals Inc COM | $3.1M | 41.8K | 0.6% | ▲New New position | |
| 28 | Maplight Therapeutics Inc COM | $2.3M | 112.1K | 0.4% | ▼−32% Reduced · −52K sh | |
| 29 | Relay Therapeutics Inc COM | $1.8M | 181.5K | 0.4% | ▲New New position | |
| 30 | Snowflake Inc COM SHS | $1.5M | 10.0K | 0.3% | —Held | |
| 31 | Aardvark Therapeutics Inc COM | $1.2M | 316.6K | 0.2% | ▲New New position | |
| 32 | Tectonic Therapeutic Inc COM | $1.2M | 37.6K | 0.2% | ▲New New position | |
| 33 | Ultragenyx Pharmaceutical In COM | $827K | 39.5K | 0.2% | ▲New New position | |
| 34 | Karyopharm Therapeutics Inc COM NEW | $295K | 53.0K | 0.1% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | AXSOME THERAPEUTICS INCAXSM | $5.9M | 35K |
| CALL · bullish | KARYOPHARM THERAPEUTICS INCKPTI | $279K | 50K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.